{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:22:01Z","timestamp":1791278521433,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,17]],"date-time":"2014-10-17T00:00:00Z","timestamp":1413504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00280-014-2609-3","type":"journal-article","created":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T09:44:29Z","timestamp":1413452669000},"page":"17-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"H. S.","family":"Hochster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Uboha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Messersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. J.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. H.","family":"ONeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Denlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. G.","family":"Leichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Leichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,17]]},"reference":[{"key":"2609_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11\u201330","journal-title":"CA Cancer J Clin"},{"key":"2609_CR2","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1245\/s10434-006-9146-1","volume":"14","author":"A Muratore","year":"2007","unstructured":"Muratore A, Zorzi D, Bouzari H et al (2007) Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 14:766\u2013770","journal-title":"Ann Surg Oncol"},{"key":"2609_CR3","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","volume":"27","author":"S Kopetz","year":"2009","unstructured":"Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677\u20133683","journal-title":"J Clin Oncol"},{"key":"2609_CR4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.clcc.2011.03.004","volume":"10","author":"DJ Renouf","year":"2011","unstructured":"Renouf DJ, Lim HJ, Speers C et al (2011) Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis. Clin Colorectal Cancer 10:97\u2013101","journal-title":"Clin Colorectal Cancer"},{"key":"2609_CR5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","volume":"359","author":"CS Karapetis","year":"2008","unstructured":"Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757\u20131765","journal-title":"N Engl J Med"},{"key":"2609_CR6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/DCR.0b013e31823c08b3","volume":"55","author":"MF Kalady","year":"2012","unstructured":"Kalady MF, Dejulius KL, Sanchez JA et al (2012) BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 55:128\u2013133","journal-title":"Dis Colon Rectum"},{"key":"2609_CR7","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","volume":"29","author":"E Cutsem Van","year":"2011","unstructured":"Van Cutsem E, Kohne CH, Lang I et al (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011\u20132019","journal-title":"J Clin Oncol"},{"key":"2609_CR8","doi-asserted-by":"crossref","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","volume":"26","author":"F Nicolantonio Di","year":"2008","unstructured":"Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705\u20135712","journal-title":"J Clin Oncol"},{"key":"2609_CR9","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229\u2013237","journal-title":"J Clin Oncol"},{"key":"2609_CR10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.bbamcr.2007.01.012","volume":"1773","author":"K Rajalingam","year":"2007","unstructured":"Rajalingam K, Schreck R, Rapp UR et al (2007) Ras oncogenes and their downstream targets. Biochim Biophys Acta 1773:1177\u20131195","journal-title":"Biochim Biophys Acta"},{"key":"2609_CR11","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1038\/sj.onc.1210422","volume":"26","author":"PJ Roberts","year":"2007","unstructured":"Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26:3291\u20133310","journal-title":"Oncogene"},{"key":"2609_CR12","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1158\/1078-0432.CCR-11-2683","volume":"18","author":"G Migliardi","year":"2012","unstructured":"Migliardi G, Sassi F, Torti D et al (2012) Inhibition of MEK and PI3\u00a0K\/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18:2515\u20132525","journal-title":"Clin Cancer Res"},{"key":"2609_CR13","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/1535-7163.MCT-07-0231","volume":"6","author":"BR Davies","year":"2007","unstructured":"Davies BR, Logie A, McKay JS et al (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase\/extracellular signal-regulated kinase kinase 1\/2 kinases: mechanism of action in vivo, pharmacokinetic\/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6:2209\u20132219","journal-title":"Mol Cancer Ther"},{"key":"2609_CR14","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1200\/JCO.2007.14.4956","volume":"26","author":"AA Adjei","year":"2008","unstructured":"Adjei AA, Cohen RB, Franklin W et al (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139\u20132146","journal-title":"J Clin Oncol"},{"key":"2609_CR15","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1158\/1078-0432.CCR-09-2483","volume":"16","author":"U Banerji","year":"2010","unstructured":"Banerji U, Camidge DR, Verheul HM et al (2010) The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1\/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16:1613\u20131623","journal-title":"Clin Cancer Res"},{"key":"2609_CR16","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10637-010-9392-8","volume":"29","author":"J Bennouna","year":"2011","unstructured":"Bennouna J, Lang I, Valladares-Ayerbes M et al (2011) A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1\/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 29:1021\u20131028","journal-title":"Invest New Drugs"},{"key":"2609_CR17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2609_CR18","doi-asserted-by":"crossref","unstructured":"Kim K, Infante J, Cohen R et al (2011) A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors. Mol Cancer Ther 10:Abstract B225","DOI":"10.1158\/1535-7163.TARG-11-B225"},{"key":"2609_CR19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","volume":"14","author":"PA Janne","year":"2013","unstructured":"Janne PA, Shaw AT, Pereira JR et al (2013) Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 14:38\u201347","journal-title":"Lancet Oncol"},{"key":"2609_CR20","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"key":"2609_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1\u201310","journal-title":"Control Clin Trials"},{"key":"2609_CR22","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"2609_CR23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1517\/13543776.2011.577068","volume":"21","author":"JI Trujillo","year":"2011","unstructured":"Trujillo JI (2011) MEK inhibitors: a patent review 2008\u20132010. Expert Opin Ther Pat 21:1045\u20131069","journal-title":"Expert Opin Ther Pat"},{"key":"2609_CR24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT, Robert C, Hersey P et al (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107\u2013114","journal-title":"N Engl J Med"},{"key":"2609_CR25","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00280-013-2121-1","volume":"71","author":"CD Britten","year":"2013","unstructured":"Britten CD (2013) PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 71:1395\u20131409","journal-title":"Cancer Chemother Pharmacol"},{"key":"2609_CR26","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1158\/1078-0432.CCR-12-3140","volume":"19","author":"A Spreafico","year":"2013","unstructured":"Spreafico A, Tentler JJ, Pitts TM et al (2013) Rational combination of a MEK inhibitor, selumetinib, and the Wnt\/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res 19:4149\u20134162","journal-title":"Clin Cancer Res"},{"key":"2609_CR27","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1158\/1078-0432.CCR-11-1507","volume":"18","author":"MP Morelli","year":"2012","unstructured":"Morelli MP, Tentler JJ, Kulikowski GN et al (2012) Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clin Cancer Res 18:1051\u20131062","journal-title":"Clin Cancer Res"},{"key":"2609_CR28","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1002\/ijc.24604","volume":"125","author":"K Balmanno","year":"2009","unstructured":"Balmanno K, Chell SD, Gillings AS et al (2009) Intrinsic resistance to the MEK1\/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1\/2 signalling and\/or strong PI3\u00a0K signalling in colorectal cancer cell lines. Int J Cancer 125:2332\u20132341","journal-title":"Int J Cancer"}],"updated-by":[{"DOI":"10.1007\/s00280-014-2625-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000}}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2609-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2609-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2609-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T07:48:21Z","timestamp":1565941701000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2609-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,17]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2609"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2609-3","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00280-014-2625-3","asserted-by":"object"}]},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,17]]}}}